Vaxcyte, Inc.'s stock fell 50% despite positive vaccine results. See how FDA uncertainty, competition, and Phase 3 delays ...

To protect your child, their doctor will give them the pneumococcal conjugate vaccine (PCV). "This is a great example of a vaccine that protects against invasive disease from a bacteria we see causing ...

The shots on your child's vaccine schedule all play an important role in protecting your little one from preventable illnesses. One of them — pneumococcal conjugate vaccine (PCV) — targets a ...

Vaxcyte Inc. characterized its latest phase II data with VAX-24 as positive but Wall Street wasn’t so sure about the dose-finding outcomes with the 24-valent pneumococcal conjugate vaccine (PCV), and ...

The pneumococcal conjugate vaccine – codenamed PCV21/GBP410 – has started pivotal trials in the prevention of both paediatric Streptococcus pneumoniae, which remains a major public health ...

With multiple blockbuster products advancing in its pipeline, ongoing technological breakthroughs, and the expansion of its international business landscape ... s pioneering PCV13i [13-valent ...

Merck MRK announced that the European Commission (“EC”) has approved its 21-valent pneumococcal conjugate vaccine (“PCV”), Capvaxive, for the prevention of invasive pneumococcal disease ...

As U.S. regulatory uncertainty swirls around the vaccine space and health care in general, Vaxcyte Inc. stands poised for a readout of phase II infant data by the end of this quarter with VAX-24, the ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).